Produkt
How it all started
From Tesla Medical to Stimvia
Our company was founded in 2014 under the name Tesla Medical by Lukáš Doskočil conjunction with specialists from 2nd Medical Faculty of Charles University in Prague in order to develop a revolutionary technology capable of changing people’s lives for better.
The result of the cooperation is URIS®, a unique technology that enables non-invasive stimulation of deep brain structures for the treatment of a range of chronic diseases.
Our key technology and its application is protected by over 71 patents throughout the EU, Japan, and the USA. We are also honored to have the CE mark from one of the most prestigious notified bodies, the renowned German institution, TÜV SÜD.
Scientific Advisory Board
Prof. Bertil Blok, MD, PhD
Chairman of the Scientific Advisory Board
Bertil FM Blok
Associate Professor Urology / Full Professor appointment pending
Sector Head Functional Urology and Neuro-Urology
Erasmus Medical Center
Mr. Blok’s education began in Rotterdam’s Erasmus Medical Center, where the university MD cum laude in 1988 and PhD cum laude in 1998 at the University Medical Center Groningen.
Mr. Blok’s work went to Resident Urology University Medical Center Amsterdam and McGill, Montreal.
His research focus of is on optimization of treatment in functional urology using basic, translational and clinical research. He is author of more than 100 peer reviewed papers, mainly as first or last author.
See: pubmed-ncbi-nlm-nih-gov
Prof. Jan Krhut, MD
Scientific Advisory Board
Prof. Jan Krhut served as the head of the Urology Clinic at the University Hospital of Ostrava for 15 years. He maintains a faculty position as a Professor of Medical Science at lecture the University and is also active in the Czech Urological Society. Since the beginning of his professional career, Prof. Krhut has specialized in adult functional urology where he focuses on the diagnosis and treatment of bladder and pelvic floor disorders. His work has been widely internationally recognized.
David R. Staskin, MD
Scientific Advisory Board
David R. Staskin, MD is an internationally recognised expert in urology, particularly in female incontinence, urodynamics and neuro-urology. He serves as Associate Professor of Urology at Tufts University and is affiliated with St. Elizabeth’s Medical Center in Boston.
During his career, he has worked at prestigious universities including Harvard, Cornell and Boston University. He is the author of more than 145 scientific publications and co-editor of three editions of the respected textbook Female Urology and Urogynecology. He holds eight patents and is the inventor of the SPARC™ and RetroArc™ systems for the treatment of female stress urinary incontinence. He co-founded UroCure and is actively involved in leading professional societies such as AUGS and SUFU.
Prof. Alan J. Wein, MD, PhD (Hon), FACS
Scientific Advisory Board
Professor Alan J. Wein is among the leading experts in urology and functional disorders of the lower urinary tract. At Stimvia, he serves as a member of the Scientific Advisory Team and brings extensive clinical and academic expertise in Overactive Bladder, urological indications and international treatment standards.
During his career, he has worked, among other institutions, at the University of Pennsylvania, where he held long-standing leadership roles in urology. His involvement strengthens Stimvia’s clinical and scientific background as the URIS® device continues to be developed and brought to international markets.
Stimvia team
Russ Mably
Chief Executive Officer
Russ Mably leads STIMVIA’s global growth and transformation, with a clear ambition: to establish STIMVIA as a world leader in personalised, non-invasive neuromodulation.
As CEO, Russ is responsible for the company’s global strategy, commercialisation and international expansion, driving the transition of STIMVIA’s proprietary neuromodulation technology from clinical innovation to a scalable global platform. His focus is on accelerating market access, building strategic partnerships and bringing personalised neuromodulation to more patients, in more conditions and across more healthcare settings.
Russ brings more than 20 years of experience building, scaling and commercialising international medical technology businesses. Before joining STIMVIA, he served as CEO of CELOX Medical, where he led international growth and strengthened the company’s position in haemostatic and wound care solutions.
At STIMVIA, Russ is focused on one defining opportunity: to change the way neurological and chronic conditions are treated by making personalised neuromodulation more accessible, more precise and more patient-centric.
Lukas Doskocil
Founder & Chief Product Officer
Since the beginning of his career, Lukas Doskocil has been involved in the development, production and commercialisation of medical devices.
After graduating from the College of International and Public Relations Prague, Lukas began working in the start-up environment and founded Stimvia (Tesla Medical) in 2014. His areas of interest include data analysis and research.
At Stimvia, Lukas has put together a stable team of experienced professionals motivated to change the way patients with various diseases are treated via non-invasive and safe neuromodulation. In his role as Chief Product Officer, he focuses on product strategy, technology development and the advancement of Stimvia’s next-generation neuromodulation platform.
Lukas Peter, PhD
QA & Regulatory Affairs
Lukas Peter specializes in medical device development with a focus on a compliance with regulatory requirements that have significant impact on product development. As a Stimvia CTO, Lukas has managed the URIS® development project since the very beginning and optimized QMS processes in line with regulatory requirements such that the final product meets the highest technical and patient safety standards. Lukas received his PhD in a Technical Cybernetics program, where researched neuromodulatory therapy and also actively participated in projects focused on electrical stimulation. His scientific insight coupled together with his knowledge of regulatory requirements enables him to manage Stimvia’s product development in line with modern requirements and trends.
Laura Edwards
Vice President, Commercial Operations
Laura Edwards is responsible for building the commercial and operational foundations needed to support STIMVIA’s continued growth. Her role spans commercial execution, market development, organisational readiness and the development of scalable processes for the company’s international expansion.
Her background combines commercial strategy with operational leadership across the medical technology sector. She has developed and implemented strategies supporting new product launches, international expansion and sustainable revenue growth, with experience including the commercialisation of healthcare innovations in women’s health.
Andy Sutcliffe
Vice President, Strategic Marketing
With more than three decades of experience across the global healthcare industry, Andy Sutcliffe brings extensive expertise in strategic marketing, market development and the commercialisation of innovative medical technologies. At STIMVIA, he is responsible for strategic marketing, helping to build awareness, adoption and international market development for the company’s neuromodulation platform.
Before joining STIMVIA, Andy was Global Strategic Marketing Director at CELOX Medical and running the women’s health division in CELOX PPH Ltd. During his career, he has helped launch healthcare technologies in more than 45 countries and held leadership roles at companies including Johnson & Johnson, Zimmer Biomet, Stryker, Corin Orthopaedics and STERIS.
David da Silva, Ph.D.
Director of Global Distribution and Strategic Partnerships
At Stimvia, David da Silva focuses on global distribution, market development and building business partnerships for the international launch of the URIS® device. He brings more than ten years of experience in commercial leadership in MedTech and healthcare technologies, including at Medtronic, Stryker and Ascendis Health.
His role is to help Stimvia enter new markets, set up scalable distribution models and develop partnerships in Europe, Latin America and other priority regions. He connects business strategy with an understanding of the clinical environment and the needs of healthcare systems so that innovative non-invasive neuromodulation can reach as many patients as possible.
Iveta Koňaříková
Sales Representative for the Czech and Slovak Republics
At Stimvia, Iveta Koňaříková focuses on business development in the Czech and Slovak markets. She is in contact with healthcare facilities, physicians and other partners, to whom she presents URIS® therapy and helps identify specific opportunities for its use in clinical practice. She connects the business side with the practical functioning of the therapy in the field, from the first contact and arranging cooperation through to ensuring that the technology reaches the places where it can help patients the most.
